Specifically, 1 lot of Irbesartan tablets and 7 lots of Irbesartan HCTZ tablets are being recalled by Prinstin Pharmaceuticals, who said the drugs contained unacceptable levels of Nitrosodiethylamine (NDEA) a likely human carcinogen (cancer-causing substance).

The ingredients were manufactured by Zheijiang Huahai Pharmaceuticals, a Chinese company that has been linked to a number of recent recalls over prescription blood pressure meds.

Specific products affected by the latest recall include:

  • IRBESARTAN TABLETS 300MG 90CT 43547-376-09 331B18009 02/2021 8/9/2018
  • IRBESARTAN/HCTZ 300MG/12.5MG 30CT TABLETS 43547-331-03 327A18001 03/2021 7/10/2018
  • IRBESARTAN/HCTZ 300MG/12.5MG 30 CT TABLETS 43547-331-03 327A18002 03/2021 7/10/2018
  • IRBESARTAN/HCTZ 300MG/12.5MG 90CT TABLETS 43547-331-09 327B18008 03/2021 7/10/2018
  • IRBESARTAN/HCTZ 300MG/12.5MG 90CT TABLETS 43547-331-09 327B18009 03/2021 7/10/2018
  • IRBESARTAN/HCTZ 150MG/12.5MG 30CT 43547-330-03 325D18004 03/2021 7/10/2018
  • IRBESARTAN/HCTZ 150MG/12.5MG 90CT TABLETS 43547-330-09 325B18004 03/2021 8/24/2018
  • IRBESARTAN/HCTZ 150MG/12.5MG 30CT TABLETS

Source: ABC KGUN 9

Posted by Ray Simon

Ray Simon is a veteran copywriter with more than a decade's worth of experience in the field. He studied journalism at Vanderbilt University, graduating Cum Laude in 2007. Ray currently specializes in writing content and news articles for independent publications.

All Posts